Medistep Healthcare IPO Set at ₹43: Key Dates, Financials & Investor Guide

New Delhi’s healthcare sector buzzes as Medistep Healthcare Limited announces its IPO priced at ₹43 per share. Opening August 8, 2025, this fixed-price offering aims to raise ₹16.09 crore, spotlighting a company that’s doubled profits in a year. For investors eyeing India’s booming hygiene and pharma market, this IPO could be a prescription for growth.

Why Should Investors Monitor the Medistep IPO?

Medistep’s explosive financial trajectory makes it a standout. Revenue surged 27% to ₹49.65 crore in FY25 (vs. ₹39.07 crore in FY24), while net profit jumped 25% to ₹4.14 crore. EBITDA margins held strong at 11.3%, reflecting operational efficiency in manufacturing sanitary pads and distributing pharmaceuticals. The company’s acquisition of M/s MG Pharma in 2024 expanded its distribution reach, tapping into rising domestic and global demand for hygiene products.

CEO Girdhari Lal Prajapati states, “This IPO fuels our manufacturing expansion and working capital needs. Our diversified portfolio positions us to lead in health and hygiene solutions.” With India’s feminine hygiene market projected to grow at 14% CAGR (FICCI 2024), Medistep’s timing aligns with macroeconomic tailwinds.

How to Apply for the Medistep Healthcare IPO

The IPO opens August 8–12, 2025, with shares listing on NSE Emerge by August 18. Key details:

• Lot Size: 3,000 shares (₹129,000 per lot)
• Reservations:
  • Retail Investors: 17.79 lakh shares (47.5%)
  • Non-Institutional: 17.76 lakh shares (47.4%)
  • Market Maker: 1.89 lakh shares (5.1%)
    Post-issue, Medistep’s market cap will hit ₹61.10 crore. Fast Track Finsec is lead manager; Cameo Corporate Services handles registrar duties.

Strategic Use of Proceeds & Risks

₹16.09 crore raised will fund:

1. Machinery purchases for manufacturing expansion,
2. Working capital requirements,
3. General corporate expenses.
   While growth metrics are robust, investors should note risks in the Red Herring Prospectus (RHP), including supply-chain dependencies and regulatory hurdles. SEBI emphasizes that RHP approval isn’t an endorsement—scrutinize disclosures at Medistep’s RHP portal or NSE’s Emerge platform.

For retail investors, Medistep’s IPO merges aggressive growth with India’s healthcare boom. Yet, consult financial advisors and dissect the RHP’s risk factors. This isn’t just a stock—it’s a stake in the country’s hygiene revolution.

---

Must Know

Q1: What is Medistep Healthcare’s IPO price and lot size?
The IPO is priced at ₹43 per equity share. Each lot requires 3,000 shares, totaling ₹129,000. Subscription runs August 8–12, 2025.

Q2: How will Medistep use IPO proceeds?
Funds will upgrade manufacturing facilities, bolster working capital, and cover corporate expenses. The goal is scaling production of sanitary pads and pharmaceuticals.

Q3: What are Medistep’s financial highlights?
FY25 revenue hit ₹49.65 crore (up 27% YoY), with net profit at ₹4.14 crore. EBITDA rose 23% to ₹5.60 crore, per company filings.

Q4: When will Medistep shares list?
Listing on NSE Emerge is slated for August 18, 2025. Post-issue, market capitalization will be ₹61.10 crore.

Q5: What risks should IPO applicants consider?
Key risks include raw material volatility, regulatory changes, and competition. Review the RHP’s “Risk Factors” section thoroughly before investing.

Q6: Who can apply under the retail category?
Retail investors are allocated 47.5% of shares (17.79 lakh). Applications up to ₹200,000 qualify for this quota.